logo-loader
HemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals chief to present at immunotherapy conference

The address will highlight the fact that despite numerous advances in understanding AML, treatment remains “unsatisfactory”

1548833357_shutterstock_633513077.jpg
The event takes place in the winter resort of Whistler in March

HemoGenyx Pharmaceuticals PLC (LONHEMO) chief Dr Vladislav Sandler is set to present at a cancer immunotherapy conference in March.

At the Keystone Symposia on Molecular and Cellular Biology in Canada, he will provide an overview of the development of the company's CDX antibodies.

READ: Hemogenyx set for talks over potential licensing deal with global pharma later this month

Specifically, he will assess the potential benefit of using these antibodies for the treatment of acute myeloid leukaemia (AML) as well as the conditioning of patients for hematopoietic stem cell transplantation.

Sandler’s address will go on to highlight the fact that, despite numerous advances in understanding AML, treatment remains “unsatisfactory” and that relapsed or refractory forms of the disease are nearly always fatal.

The conference takes place in the winter resort of Whistler from March 10 to 14.

In late afternoon trading, shares in Hemogenyx were 1.6% higher at 3.25p.

In a note to clients, analysts at ‘house’ broker Northland Capital commented: “This conference is a good arena to showcase Hemogenyx’s novel therapies, as it brings together leading experts in the cancer immunotherapy sector.”

For more details click here.

 -- Adds share price, analyst comment --

Quick facts: HemoGenyx Pharmaceuticals

Price: £0.03

Market: LSE
Market Cap: £9.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read